Popular search terms:
Search Results Label
25 results found-
Seqirus announces major advances in pandemic preparedness
Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States' capacity to respond to pandemic threats.
https://www.seqirus.us/...-advances-in-pandemic-preparedness -
Seqirus Applauds the Executive Order to Accelerate Enhanced Protection
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, applauds the Administration for recognizing the urgency of ensuring Americans are better protected against seasonal and pandemic influenza threats by releasing the Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health.
https://www.seqirus.us/...otection-against-influenza-threats -
Seqirus announces next major advancement in cell-based influenza
In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.
https://www.seqirus.us/...based-influenza-vaccine-technology -
US Media Release Template Q3 2013
Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally, with extensive research and production
https://www.seqirus.us/-/media/seqirus-us/news/franchise-shipment-press-release--71116final-530-pm.pdf -
Seqirus | A World Leader in Influenza Vaccines
Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.
https://www.seqirus.us/ -
Seqirus | Latest News
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.seqirus.us/news -
Seqirus | Partnership Opportunities
Seqirus stands with our partners on the front line of public health. We are the largest fully integrated commercialisation partner in Australia and New Zealand. Learn more.
https://www.seqirus.us/partnering -
New Clinical Data Reinforces the Ability of MF59 Adjuvanted Seasonal
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
https://www.seqirus.us/...al-and-pandemic-influenza-vaccines -
Seqirus Announces U.S. $140 Million Manufacturing Expansion to
The expansion will allow Seqirus to increase capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.
https://www.seqirus.us/...40-million-manufacturing-expansion -
Seqirus | Annual Disclosures
Seqirus, as a member of the CSL group, is bound by CSL's Code of Responsible Business Practice. Access our annual financial and diversity disclosures.
https://www.seqirus.us/...rporate-responsibility/disclosures